Cargando…
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression
BACKGROUND: Hereditary transthyretin-mediated amyloidosis, also known as ATTRv amyloidosis (v for variant), is a rare, autosomal dominant, fatal disease, in which systemic amyloid progressively impairs multiple organs, leading to disability and death. The recent approval of disease-modifying therapi...
Autores principales: | Adams, David, Algalarrondo, Vincent, Polydefkis, Michael, Sarswat, Nitasha, Slama, Michel S., Nativi-Nicolau, Jose |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489116/ https://www.ncbi.nlm.nih.gov/pubmed/34602081 http://dx.doi.org/10.1186/s13023-021-01960-9 |
Ejemplares similares
-
Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus
por: Grandis, M., et al.
Publicado: (2020) -
ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable
por: Brannagan, Thomas H., et al.
Publicado: (2021) -
Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
por: Manti, Filippo, et al.
Publicado: (2022) -
Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion
por: Surbek, Daniel, et al.
Publicado: (2019) -
European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
por: Shovlin, Claire L., et al.
Publicado: (2018)